Article Text

Download PDFPDF

Inhibition of mTORC2/Akt signaling to enhance the therapeutic potential of CD8 T cells
  1. Lianjun Zhang1,
  2. Benjamin Tschumi1,
  3. Susanne Oberle2,
  4. Markus Ruegg3,
  5. Michael Hall3,
  6. Dietmar Zehn2,
  7. Jean-Pierre Mach4,
  8. Alena Donda1 and
  9. Pedro Romero1
  1. Aff1 grid.9851.50000 0001 2165 4204Ludwig Cancer Research of University of Lausanne Switzerland Epalinges Switzerland
  2. Aff2 grid.482333.dSwiss Vaccine Research Institute, Lausanne, Lausanne Switzerland, Switzerland
  3. Aff3 grid.6612.30000000419370642BiozentrumUniversity of Basel Basel Switzerland, Switzerland
  4. Aff4 grid.9851.50000000121654204Department of BiochemistryUniversity of Lausanne Epalinges Switzerland, Switzerland

Statistics from Altmetric.com

Meeting abstracts

CD8 T cells mediate protective immune responses against infections and cancer. Upon infection, antigen-specific naïve CD8 T cells are activated and differentiate into short-lived effector (SLEC) and memory precursor cells (MPEC). The T cell intrinsic signaling pathways underlying this differentiation remain largely unresolved. Here we show that Rictor, the core component of mammalian target of rapamycin complex 2 (mTORC2), regulates SLEC and MPEC commitment. Rictor deficient T cells form enhanced memory without dampening effector function, have increased IL-2 secretion capacity and mediate more potent recall responses. Mechanistically, enhanced memory formation in the absence of functional mTORC2 was associated with transcriptional and metabolic reprogramming by Eomes and Tcf-1 upregulation, repression of T-bet and nuclear stabilization of Foxo1. Elimination of Foxo1 reversed the increased MPECs differentiation and IL-2 production in Rictor KO mice. Effective T cell therapy against cancer depends highly on the generation of long-term persistent memory CD8 T cells. Our preliminary data show that Rictor deficient CD8 T cells show superior tumor protection effects in mouse melanoma model. Together, our study identifies mTORC2 as a central regulator of CD8 T cell differentiation and inhibition of mTORC2 or Akt might represent an effective strategy for both adoptive cell transfer and vaccine-based cancer therapies.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.